CGRP antagonists vs traditional migraine prophylaxis (topiramate, propranolol, amitriptyline) — when to escalate?

A 35-year-old female with chronic migraine (> 15 headache days/month) has failed topiramate and amitriptyline due to side effects. She is now on overusing triptans. What is the current evidence for anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) in chronic migraine? When do we consider gepants (rimegepant, atogepant) as preventives? Are there cardiovascular contraindications specific to CGRP pathway drugs?